GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Mtor | decreases activity | ISO | MTOR (Homo sapiens) | 6480464 | CTD | sorafenib results in decreased activity of MTOR protein | PMID:21601561 PMID:23036488 | Mtor | decreases expression | ISO | MTOR (Homo sapiens) | 6480464 | CTD | sorafenib results in decreased expression of MTOR mRNA | PMID:26409325 | Mtor | decreases phosphorylation | ISO | MTOR (Homo sapiens) | 6480464 | CTD | sorafenib results in decreased phosphorylation of MTOR protein | PMID:20054642 | Mtor | increases expression | ISO | MTOR (Homo sapiens) | 6480464 | CTD | sorafenib results in increased expression of MTOR protein | PMID:25416439 | Mtor | increases phosphorylation | ISO | MTOR (Homo sapiens) | 6480464 | CTD | sorafenib results in increased phosphorylation of MTOR protein | PMID:21187475 | Mtor | multiple interactions | ISO | MTOR (Homo sapiens) | 6480464 | CTD | [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased activity of MTOR protein; [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; arsenic trioxide inhibits the reaction [sorafenib results in increased expression of MTOR protein] | PMID:21187475 PMID:21601561 PMID:23036488 PMID:25416439 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |